Impact of everolimus on HIV persistence post kidney (and kidney/pancreas) or liver transplant

Investigator: Peter G. Stock, MD, PhD
Sponsor: Novartis Oncology

Location(s): United States


Zortress (everolimus), the 40-O-(2-hydroxyethyl)-derivative of rapamycin, is an mTOR inhibitor approved for rejection prophylaxis in kidney transplant recipients. mTOR inhibition may favorably impact the HIV viral reservoir, and we hypothesize that adding everolimus to the transplant immunosuppressive regimen of HIV positive transplant recipients will decrease HIV persistence in CD4+ lymphocytes.